CureVac N.V., a biotech company specializing in mRNA-based medicines, announced the resolution of its patent litigation with Pfizer and BioNTech regarding mRNA-based COVID-19 vaccines. Under the settlement, CureVac and its affiliate GSK will receive a total payment of $740 million, along with single-digit royalties on future U.S. sales of COVID-19 vaccines. Additionally, CureVac will receive $50 million from GSK by monetizing a portion of U.S. product royalties from a prior agreement. The settlement includes granting Pfizer and BioNTech a non-exclusive license to manufacture and sell mRNA-based COVID-19 and influenza products in the U.S., which will expand to a global license following BioNTech's acquisition of CureVac. This acquisition, announced earlier in June 2025, is set to proceed as planned, subject to regulatory approval.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。